Key result
Personalized LGE-T1 virtual-heart technology predicts VA in HCM with ~80% accuracy, outperforming current clinical models.
Why the study?
Current clinical risk stratification criteria inadequately identify hypertrophic cardiomyopathy patients at risk of sudden cardiac death from ventricular arrhythmias who need primary prevention.
Does an imaging-based computational heart model improve the prediction of future ventricular arrhythmias in patients with hypertrophic cardiomyopathy compared to current clinical risk predictors?
Population
Patients with hypertrophic cardiomyopathy
Comparison
Imaging-based computational heart models vs current clinical risk predictors
Loading...
May support personalized VA risk stratification in HCM; hypothesis-generating and requires prospective validation before practice change.
Observational (n=26)
Single-blind
No
Does an imaging-based computational heart model improve the prediction of future ventricular arrhythmias in patients with hypertrophic cardiomyopathy compared to current clinical risk predictors?
Absolute Event Rate: 80.1% vs 46.2%
Personalized computational heart models incorporating CMR and T1 mapping data can accurately predict ventricular arrhythmia risk in HCM patients, outperforming standard clinical predictors.
A 2022 study conducted an observational in Hypertrophic cardiomyopathy (n=26). LGE-T1 virtual-heart technology vs. ACCF/AHA and ESC clinical risk assessment guidelines was evaluated on Prediction of ventricular arrhythmia (VA) events. The personalized LGE-T1 virtual-heart technology achieved 80.1% accuracy, 84.6% sensitivity, and 76.9% specificity in forecasting future ventricular arrhythmia events in HCM patients, outperforming current clinical risk models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: